The publication provides incremental scientific validation for GX-03's mechanism but does not change the binary Phase 2 readout expected mid-2026. Monitor for the subsequent mechanistic manuscript and the Phase 2 topline results as the next major catalysts.
Price Chart
Executive Summary
Turn Therapeutics announced a peer-reviewed publication in the Journal of Dermatological Treatment showing that GX-03 achieved a statistically significant reduction in disease severity in a murine dermatitis model characterized by IL-36 expression. This is the first in a planned series of publications supporting the scientific rationale for GX-03, which is currently in Phase 2 evaluation for moderate-to-severe atopic dermatitis with topline results expected in mid-2026.
Key Facts
- GX-03 achieved mean IGA score of 1.44 vs 3.00 in controls (p=0.0003) in murine IL-36 model
- No treatment-related adverse effects observed
- First in a planned series of peer-reviewed publications on GX-03
- GX-03 currently in Phase 2 RCT for moderate-to-severe atopic dermatitis; topline results expected mid-2026
- Subsequent manuscript already in review characterizing mechanistic implications
Financial Impact
No financial data provided; pre-revenue clinical-stage biotech with $171M market cap
Risk Factors
- Preclinical murine data may not translate to human clinical outcomes
- Phase 2 topline results are the true catalyst; publication alone does not de-risk the program
- Clinical-stage biotech with no approved products or revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-061244 |
| Document: ea029186601ex99-1.htm | 0001213900-26-061244 |
| Document: 0001213900-26-061244-index-headers.html | 0001213900-26-061244 |
| Document: 0001213900-26-061244-index.html | 0001213900-26-061244 |
| Document: 0001213900-26-061244.txt | 0001213900-26-061244 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEF 14A | $10.47 | awaiting T+60 | — | $10.54 (+0.67%) |
Oct 6, 2026 20d ago | 8-K | $12.10 | awaiting T+60 | — | $10.54 (−12.89%) |
Sep 10, 2026 6w ago | 8-K | $13.38 | awaiting T+60 | — | $10.54 (−21.23%) |
Sep 9, 2026 6w ago | 8-K | $13.75 | awaiting T+60 | — | $10.54 (−23.35%) |
Aug 18, 2026 10w ago | 8-K | $9.99 | awaiting T+60 | — | $10.54 (+5.51%) |
Jul 7, 2026 16w ago | 8-K | $9.71 $14.39 | ▲ +48.20% | ▲ +46.20% | $10.54 (+8.55%) |
Jun 3, 2026 20w ago | 8-K | $6.02 $10.11 | ▲ +67.94% | ▲ +65.44% | $10.54 (+75.08%) |
Jun 1, 2026 21w ago | 8-K | $6.33 $9.73 | ▲ +53.71% | ▲ +52.48% | $10.54 (+66.51%) |
May 27, 2026 21w ago | 8-K | $5.29 $9.54 | ▲ +80.34% | ▲ +78.46% | $10.54 (+99.24%) |
May 19, 2026 23w ago | 8-K | $4.55 $9.86 | ▲ +116.70% | ▲ +110.41% | $10.54 (+131.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers